In May of 2011, CryoLife completed the acquisition of Cardiogenesis Corporation. Now a wholly owned subsidiary of CryoLife, Cardiogenesis specializes in the treatment of cardiovascular disease and the sale of devices that treat severe angina. Its market leading FDA-approved Holmium: YAG laser system and single use fiber-optic delivery systems are used to perform a surgical procedure known as Transmyocardial Revascularization (TMR). Published long term results demonstrate the efficacy of the TMR treatment in patients suffering from chronic stable angina refractory to medical management, when stenting or bypass surgery is no longer an option in the treatment for angina. The Cardiogenesis laser system is approved by the FDA for distribution in the U.S. and is CE Marked for use in Europe. TMR is accepted as a meaningful therapy and treatment for refractive angina by the American College of Cardiology, American Heart Association and the Society of Thoracic Surgery. In addition, Cardiogenesis is building on the TMR platform in combining laser therapy with the delivery of autologous cell therapy in a single delivery system. As a subsidiary of CryoLife, Cardiogenesis is located in Kennesaw, Georgia a suburb of northwest Atlanta.